The packet definition describes the inherited ichthyoses as an etiologically heterogeneous group caused by mutations in various genes important for keratinocyte differentiation and epidermal barrier function. No specific genes or inheritance patterns are certified in this packet, so none are named here. Acquired forms are described as occurring alongside certain autoimmune, inflammatory, metabolic, endocrine, or infectious diseases or malignancies.

Diagnostic criteria and testing methods are not certified in this packet.

No FDA-approved therapies or orphan drug records are present in this packet, and treatment coverage is not certified here. Registered studies describe several approaches under evaluation: an emollient study (NCT07783165, Dermal Laboratories Ltd, not yet recruiting), a comparison of cholesterol cream and urea cream (NCT07689435, Institute of Dermatology, Thailand, not yet recruiting), and a study of body and scalp wraps in hereditary ichthyosis (NCT05979506, University Hospital, Toulouse, recruiting).

Prognosis is not certified in this packet.

ClinicalTrials.gov records in the packet include NCT06136403, a Phase 2 open study of deucravacitinib in adults with inflammatory genodermatoses (Centre Hospitalier Universitaire de Nice, recruiting); NCT06362447, a Phase 2 study of injectable gentamicin in hereditary ichthyosis (University Hospital, Toulouse, not yet recruiting); NCT06545695, a Phase 1 study of epidermal growth factor receptor inhibition for keratinopathies (Northwestern University, not yet recruiting); and NCT05954416, a registered cohort (RaDiCo-FARD) sponsored by INSERM and recruiting. The Foundation For Ichthyosis & Related Skin Types is listed in the packet as a patient organization with a registry.